Welcome Guest | Register / Login

Prostate Cancer Market Research Reports

Sort By
Title Published Price
Global Prostate Cancer Partnering 2010 to 2016
By Current Partnering
"Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access t- the prostate cancer partnering deals and agreements entered int- by the worlds leading healthcare companie...
Jul 2016 $ 1495
Prostate Cancer Treatment Drugs Industry Forecasts - China Focus
By AMID
This study focuses on China's Prostate Cancer Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in C...
Mar 2016 $ 1000
Metastatic Prostate Cancer-Pipeline Insights, 2016
By Delve Insight
SUMMARY DelveInsight's, " Metastatic Prostate Cancer-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Metastatic Prostate Cancer. The DelveInsight'sReport covers the...
Jan 2016 $ 1250
Metastatic Hormone Refractory Prostate Cancer-Pipeline Insights, 2016
By Delve Insight
SUMMARY DelveInsight's, " Metastatic Hormone Refractory Prostate Cancer-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Metastatic Hormone Refractory Prostate Cance...
Jan 2016 $ 1250
Global Prostate Cancer Therapeutics Market to 2020
By Renub Research
Global Prostate Cancer Therapeutics Market Overview The prostate cancer drugs market is expected to nearly double by 2020, due to the introduction of new, more expensive drugs. Prostate Cancer is the most frequently diagno...
Nov 2015 $ 1200
Global Prostate Cancer Therapeutic Market to 2020
By iGate Research
Prostate Cancer remains a top priority for health systems around the world as incidence level rises, fueled by growing and aging populations. The main drivers for the prostate cancer market are the increase in the global aging population, innovati...
May 2015 $ 1000
Disease and Therapy Review: Prostate Cancer
By Timely Data resources
The Prostate Cancer Disease and Therapy Review provides an overview of the disease and related conditions, with  incidence, prevalence and mortality numbers and percentages for major countries worldwide,  and an overview of treatment.&nb...
Feb 2013 $ 950
Prostate Cancer – Pipeline Review, H1 2012
By Global Markets Direct
Prostate Cancer – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Prostate Cancer - Pipeline Review, H1 2012', provides an overview of the Prostate Cancer therapeutic pipeline. This report provides in...
Feb 2012 $ 500
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2012
By GlobalData
GlobalData's clinical trial report, “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2012" provides data on the Hormone Refractory (Castration Resistant, Androgen-In...
Jan 2012 $ 1000
Hormone Refractory Prostate Cancer - Pipeline Review, H2 2011
By Global Markets Direct
Hormone Refractory Prostate Cancer - Pipeline Review, H2 2011SummaryGlobal Markets Direct’s, 'Hormone Refractory Prostate Cancer - Pipeline Review, H2 2011', provides an overview of the Hormone Refractory Prostate Ca...
Nov 2011 $ 500
Prostate Cancer - Pipeline Review, H2 2011
By Global Markets Direct
Report SummaryGlobal Markets Direct’s, 'Prostate Cancer - Pipeline Review, H2 2011', provides an overview of the Prostate Cancer therapeutic pipeline. ...
Sep 2011 $ 500
Hormone Refractory Prostate Cancer - Pipeline Review, Q2 2011
By Global Markets Direct
Hormone Refractory Prostate Cancer - Pipeline Review, Q2 2011SummaryGlobal Markets Direct’s, 'Hormone Refractory Prostate Cancer - Pipeline Review, Q2 2011', provides an overview of the Hormone Refractory Prostate Cance...
May 2011 $ 500
FDA Approves Zytiga (Abiraterone Acetate) for the Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer
By GlobalData
Report SummaryIt has been an exciting year for prostate cancer therapeutics. On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abirateron...
May 2011 $ 500
Endothelin A Receptor Antagonist (atrasentan) Fails to Demonstrate an Advantage in the Treatment of Advanced Prostate Cancer
By GlobalData
Report SummaryThis year another endothelin A receptor antagonist failed to demonstrate an advantage for advanced prostate cancer. With the failure of atrasentan in P...
May 2011 $ 500
Prostate Cancer - Pipeline Review, Q1 2011
By Global Markets Direct
Report SummaryGlobal Markets Direct’s, 'Prostate Cancer - Pipeline Review, Q1 2011', provides an overview of the Prostate Cancer therapeutic pipeline. This report provides information o...
Feb 2011 $ 500
The 2011-2016 World Outlook for Prostate Cancer Therapeutics
By ICON Group International, Inc.
This econometric study covers the world outlook for prostate cancer therapeutics across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in ...
Jan 2011 $ 795
The 2011-2016 Outlook for Prostate Cancer Therapeutics in Greater China
By ICON Group International, Inc.
This econometric study covers the latent demand outlook for prostate cancer therapeutics across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (...
Jan 2011 $ 495